1. Home
  2. MEC vs GLUE Comparison

MEC vs GLUE Comparison

Compare MEC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEC
  • GLUE
  • Stock Information
  • Founded
  • MEC 1945
  • GLUE 2019
  • Country
  • MEC United States
  • GLUE United States
  • Employees
  • MEC N/A
  • GLUE N/A
  • Industry
  • MEC Industrial Specialties
  • GLUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • MEC Industrials
  • GLUE Health Care
  • Exchange
  • MEC Nasdaq
  • GLUE Nasdaq
  • Market Cap
  • MEC 324.5M
  • GLUE 356.3M
  • IPO Year
  • MEC 2019
  • GLUE 2021
  • Fundamental
  • Price
  • MEC $15.78
  • GLUE $5.66
  • Analyst Decision
  • MEC Strong Buy
  • GLUE Buy
  • Analyst Count
  • MEC 3
  • GLUE 3
  • Target Price
  • MEC $20.67
  • GLUE $12.67
  • AVG Volume (30 Days)
  • MEC 117.2K
  • GLUE 1.2M
  • Earning Date
  • MEC 03-04-2025
  • GLUE 03-13-2025
  • Dividend Yield
  • MEC N/A
  • GLUE N/A
  • EPS Growth
  • MEC 53.85
  • GLUE N/A
  • EPS
  • MEC 0.59
  • GLUE N/A
  • Revenue
  • MEC $608,880,000.00
  • GLUE $14,975,000.00
  • Revenue This Year
  • MEC $0.32
  • GLUE N/A
  • Revenue Next Year
  • MEC $3.37
  • GLUE N/A
  • P/E Ratio
  • MEC $26.73
  • GLUE N/A
  • Revenue Growth
  • MEC 7.13
  • GLUE N/A
  • 52 Week Low
  • MEC $11.07
  • GLUE $3.21
  • 52 Week High
  • MEC $23.02
  • GLUE $12.40
  • Technical
  • Relative Strength Index (RSI)
  • MEC 47.71
  • GLUE 35.37
  • Support Level
  • MEC $14.53
  • GLUE $5.51
  • Resistance Level
  • MEC $15.78
  • GLUE $6.38
  • Average True Range (ATR)
  • MEC 0.44
  • GLUE 0.49
  • MACD
  • MEC 0.10
  • GLUE -0.07
  • Stochastic Oscillator
  • MEC 70.74
  • GLUE 13.22

About MEC Mayville Engineering Company Inc.

Mayville Engineering Co Inc is involved in a manufacturing partner that provides a broad range of prototyping and tooling, production fabrication, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, power sports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly and logistic services.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: